Introduction
What Is CJC-1295?
CJC-1295 is a synthetic peptide studied for its ability to stimulate the body's own production of growth hormone. It belongs to a class of compounds known as growth hormone-releasing hormone (GHRH) analogs, meaning it mimics a signaling molecule your body already makes to encourage the pituitary gland to release growth hormone.
Because natural growth hormone output declines steadily with age, peptides like CJC-1295 have drawn interest within the recovery, body-composition, and longevity communities. Rather than introducing synthetic growth hormone directly, the aim is to prompt your own glandular system to work more efficiently.
This article is educational and not medical advice. CJC-1295 has never been FDA-approved for any use, so prescribing it is unapproved rather than off-label, and CJC-1295 prescribed in the US is a compounded preparation. Whether it is appropriate for you is a clinical decision made with a qualified provider after a proper evaluation. At Protocol Health in Scarsdale, NY, peptide therapy is always physician-led and individualized.
Explore CJC-1295 Peptide TherapyQuick Answer
What does CJC-1295 do?
CJC-1295 signals the pituitary gland to release more of your own growth hormone, and in human studies it raised growth hormone and IGF-1 for days after a single injection. Patients ask about it for body composition, recovery, sleep and general vitality, but those outcomes have not been tested in published trials. It is often paired with ipamorelin; the pair has not been studied together in a published human trial.
It is important to be clear-eyed: individual responses vary, evidence in wellness contexts is still developing, and CJC-1295 is not a shortcut or a guarantee. Suitability, dosing, and monitoring are determined case-by-case by a supervising physician after labs and a full health review.
Mechanism
How does CJC-1295 work in the body?
CJC-1295 works in the body by imitating the GHRH signal that tells your pituitary to release growth hormone. Your pituitary gland naturally receives signals from growth hormone-releasing hormone (GHRH). CJC-1295 imitates that signal. In a human study of the long-acting form, growth hormone still came in pulses of normal frequency and size, but the baseline level between pulses rose about 7.5-fold, so it is not simply a copy of the natural pattern.
Some formulations of CJC-1295 are engineered to last much longer than the natural hormone, which changes how often it is given. It is often combined with a ghrelin-receptor secretagogue like ipamorelin, which works through a separate pathway, with the aim of a stronger growth hormone release.
Because growth hormone influences downstream processes such as tissue repair, metabolism, and cellular turnover, the areas of interest are wide-ranging. In real-world care, however, the emphasis is always on supervised, measured use rather than maximizing output for its own sake.
DAC vs No DAC
CJC-1295 With DAC vs CJC-1295 No DAC (Mod GRF 1-29)
CJC-1295 with DAC and CJC-1295 no DAC (Mod GRF 1-29) are two forms that behave very differently. The original compound, CJC-1295 with DAC (drug affinity complex), was engineered to bind to albumin in the bloodstream after injection, which shields it from breakdown. The version sold as CJC-1295 no DAC, also called modified GRF 1-29, lacks that albumin-binding piece and is cleared within a short time, much like the body's own GHRH.
| CJC-1295 with DAC | CJC-1295 no DAC (Mod GRF 1-29) | |
|---|---|---|
| Duration | Half-life of about 6-8 days in human studies | Short-acting; cleared quickly |
| Growth hormone pattern | Raises baseline (trough) GH while pulses continue | Produces a short pulse after each dose |
| Human data | Two small published studies in healthy adults (2006) | Little published human data under this name |
| Usual pairing | Sometimes paired with ipamorelin | Most often paired with ipamorelin |
Neither form is FDA-approved. Which one, if either, fits a patient is a physician's decision based on goals, labs and history.
The Evidence
What the Human Studies on CJC-1295 Show
CJC-1295 is one of the few wellness peptides with published, placebo-controlled human data, although that data is small, short and measures hormone levels rather than outcomes. In two randomized, double-blind, ascending-dose trials in healthy adults aged 21 to 61, a single injection of CJC-1295 raised mean growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days, IGF-1 stayed above baseline for up to 28 days after multiple doses, and no serious adverse reactions were reported. The authors reported it was particularly well tolerated at 30 or 60 micrograms per kilogram (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006).
A follow-up study in healthy men aged 20 to 40 sampled blood every 20 minutes overnight. One week after a single injection, growth hormone still came in pulses of normal frequency and size, but baseline levels rose 7.5-fold, mean growth hormone rose 46% and IGF-1 rose 45% (Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism, 2006).
Those figures describe research doses, not a protocol to follow. At Protocol Health, any CJC-1295 therapy or CJC-1295 / ipamorelin protocol is dosed and monitored individually by a physician.
Benefits
What are the potential benefits of CJC-1295?
In wellness and longevity settings, people ask about CJC-1295 for lean body composition, fat loss, exercise recovery, sleep quality, skin and overall energy. Those are goals drawn from what growth hormone does in the body, not results from CJC-1295 trials, which measured hormone levels only. What the human research does show is that CJC-1295 raises growth hormone and IGF-1 in healthy adults.
Benefits are not uniform and cannot be promised. What one person experiences may differ meaningfully from another, and outcomes depend on age, baseline hormone status, lifestyle, training, sleep, and nutrition.
For this reason, Protocol Health treats peptides as one lever within a comprehensive plan, not a standalone fix, alongside strength training, protein-forward nutrition, and attention to sleep and stress.
Candidacy
Who is a candidate for CJC-1295?
CJC-1295 may be considered for generally healthy adults pursuing recovery, body-composition, or longevity goals who have plateaued despite good fundamentals, and who want a physician-supervised approach. A thorough history and lab work help establish whether a peptide protocol makes sense for you.
It is generally not appropriate for people who are pregnant or breastfeeding, who have active cancer or a history of it, or who have certain endocrine conditions. Because growth hormone pathways interact with other systems, an honest medical review is essential before starting.
The only way to know if you are a candidate is a consultation. If you are exploring options across recovery and vitality, our team can also help you compare peptides such as sermorelin, ipamorelin, or a combined CJC-1295 / ipamorelin protocol based on your goals.
Safety
Is CJC-1295 safe? What are the side effects?
The long-term safety of CJC-1295 is unknown, and when it is used under medical supervision, reported side effects of GHRH-type peptides are typically mild and may include injection-site redness, flushing, temporary water retention, headache, or lightheadedness. Some people notice changes in appetite or sleep, especially early on.
Because CJC-1295 influences growth hormone, thoughtful clinicians monitor for effects on blood sugar and other markers over time, and adjust protocols accordingly. This is exactly why unsupervised or online-sourced peptide use is discouraged: quality, dosing, and monitoring all matter.
The FDA has flagged compounded CJC-1295 for possible immune reactions and peptide-related impurities, and says it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, with limited clinical data overall (FDA).
CJC-1295 is not FDA-approved for any use, and its human safety data come from studies lasting weeks. This section is educational, not a substitute for personalized medical advice. A qualified provider is the right person to weigh the risks and benefits for your specific situation.
The Process
What should I expect from treatment?
You should expect treatment to begin with a consultation and baseline labs so your physician understands your hormone status, metabolic markers, and health history. From there, a protocol, if appropriate, is tailored to your goals with clear guidance on administration and expectations.
CJC-1295 is usually delivered by small subcutaneous injection, and many protocols pair it with ipamorelin. Your provider will explain timing, technique, and what to watch for. Follow-up check-ins and repeat labs help track your response and fine-tune the plan.
Patience matters. Peptide-related changes tend to be gradual rather than dramatic, unfolding over weeks alongside consistent training, nutrition, and sleep. Ongoing supervision ensures the protocol continues to fit you as your goals evolve.
Our Approach
The Protocol Health approach to peptide therapy
Protocol Health takes a physician-led approach to peptide therapy as a family-owned health-optimization practice in Scarsdale, NY. We see patients in person at the Scarsdale clinic and by telehealth in New York, New Jersey, Connecticut, Florida and California. Our model is built on clinical oversight, individualized protocols and lab-informed decisions.
With peptides like CJC-1295, that means starting with your data, being honest about what the evidence does and does not support, and integrating therapy into a broader longevity and recovery strategy. Our clinical team is here to help you decide whether a peptide protocol is a smart, safe fit for your goals.
CJC-1295 is a compounded, unapproved GHRH analog that raises your own growth hormone and IGF-1, with small, short human studies behind it and no outcome trials. If you are curious whether it belongs in your plan, the next step is the Protocol Health peptide consultation, with a provider who reviews your labs and history first.
FAQ
Frequently Asked Questions
What is CJC-1295 used for?
In physician-supervised wellness and longevity settings, CJC-1295 is used to raise the body's own growth hormone, with goals such as body composition, recovery, sleep quality and vitality. Those goals have not been tested in outcome trials. CJC-1295 is not FDA-approved for any use, so appropriateness is determined case by case by a provider after evaluation.
How long does it take to see results from CJC-1295?
Responses vary widely between individuals, and results cannot be guaranteed. Because peptide-related changes tend to be gradual, many people evaluate their response over several weeks to a few months, always alongside consistent training, nutrition, and sleep. Follow-up labs help your provider track progress and adjust the protocol.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds to albumin in the blood, so a single injection lasted about a week in human studies and raised baseline growth hormone. CJC-1295 without DAC, also called Mod GRF 1-29, is short-acting and produces a brief pulse after each dose. Neither is FDA-approved, and the choice is made with a physician.
What is the difference between CJC-1295 and ipamorelin?
CJC-1295 is a GHRH analog that prompts the pituitary through the GHRH receptor, while ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor. They are often combined because the two pathways may complement each other, though the pair has not been tested together in a published trial. Your provider determines whether a combined protocol is right for you.
Is CJC-1295 legal and FDA-approved?
CJC-1295 is not FDA-approved for any use, so prescribing it is unapproved rather than off-label, and CJC-1295 prescribed in the US is compounded. It should only be used under the supervision of a qualified provider who can source it responsibly, determine suitability and monitor your response. This information is educational and not medical advice.
Does CJC-1295 have side effects?
Under medical supervision, reported side effects are usually mild and may include injection-site reactions, flushing, temporary water retention, headache, or changes in sleep or appetite. Because it affects growth hormone pathways, clinicians monitor relevant markers over time and adjust the protocol accordingly.
How is CJC-1295 administered?
CJC-1295 is typically given as a small subcutaneous injection, often paired with ipamorelin. Your provider will explain the dosing schedule, injection technique, and what to monitor, with follow-up visits and labs to fine-tune your protocol over time.
Explore